IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

The ability to control gene expression across a wide range is crucial for many fields, including bioengineering, disease ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

IMUNON (IMNN) announced new safety and immunogenicity data from ongoing analyses of results from the Company’s first Phase 1 proof-of-concept ...

Researchers develop hydrogel microspheres with data-encoding bacteria that enable room-temperature DNA storage with ...

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

PDA has released Points to Consider No. 11 Development, Classification, Manufacture, Control, and Testing of Plasmids and Vectors Used in ATMP Production on its bookstore and membership technical ...

Telegram may be among the most popular messaging services in the world, yet many still don’t know what it’s all about. The app is often name-dropped in discussions regarding online privacy and ...

Charles River Laboratories International, Inc.’s CRL leadership in outsourced drug discovery and safety testing services supports the growth in its DSA (Discovery and Safety Assessment) segment.

The global viral vector and plasmid DNA manufacturing market size was calculated at US$ 7.26 billion in 2024 and is projected to reach around US$ 43.04 billion by 2034, expanding at a compound annual ...